Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

Related Citations for PubMed (Select 24378930)

1.

Safety profile of anti-gout agents: an update.

Stamp LK.

Curr Opin Rheumatol. 2014 Mar;26(2):162-8. doi: 10.1097/BOR.0000000000000031. Review.

PMID:
24378930
2.

Pegloticase for treating refractory chronic gout.

George RL Jr, Sundy JS.

Drugs Today (Barc). 2012 Jul;48(7):441-9. doi: 10.1358/dot.2012.48.7.1813475. Review.

PMID:
22844655
3.

Diabetes and gout: efficacy and safety of febuxostat and allopurinol.

Becker MA, MacDonald PA, Hunt BJ, Jackson RL.

Diabetes Obes Metab. 2013 Nov;15(11):1049-55. doi: 10.1111/dom.12135. Epub 2013 Jun 12.

4.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.

N Engl J Med. 2005 Dec 8;353(23):2450-61.

5.

Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.

Ernst ME, Fravel MA.

Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033. Review.

PMID:
20109996
6.

Update on emerging urate-lowering therapies.

Chohan S, Becker MA.

Curr Opin Rheumatol. 2009 Mar;21(2):143-9. doi: 10.1097/BOR.0b013e328325bd94. Review. Erratum in: Curr Opin Rheumatol. 2010 Jan;22(1):106.

PMID:
19339925
7.

Urate-lowering therapy for gout: focus on febuxostat.

Love BL, Barrons R, Veverka A, Snider KM.

Pharmacotherapy. 2010 Jun;30(6):594-608. doi: 10.1592/phco.30.6.594. Review.

PMID:
20500048
8.

Long-term safety of pegloticase in chronic gout refractory to conventional treatment.

Becker MA, Baraf HS, Yood RA, Dillon A, Vázquez-Mellado J, Ottery FD, Khanna D, Sundy JS.

Ann Rheum Dis. 2013 Sep 1;72(9):1469-74. doi: 10.1136/annrheumdis-2012-201795. Epub 2012 Nov 10.

9.

Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.

White WB, Chohan S, Dabholkar A, Hunt B, Jackson R.

Am Heart J. 2012 Jul;164(1):14-20. doi: 10.1016/j.ahj.2012.04.011. Epub 2012 Jun 13.

PMID:
22795277
10.

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

Wells AF, MacDonald PA, Chefo S, Jackson RL.

BMC Musculoskelet Disord. 2012 Feb 9;13:15. doi: 10.1186/1471-2474-13-15.

11.

Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.

Chohan S.

J Rheumatol. 2011 Sep;38(9):1957-9. doi: 10.3899/jrheum.110092. Epub 2011 Jul 1.

PMID:
21724706
12.

Pharmacokinetics considerations for gout treatments.

Richette P, Frazier A, Bardin T.

Expert Opin Drug Metab Toxicol. 2014 Jul;10(7):949-57. doi: 10.1517/17425255.2014.915027. Epub 2014 May 8. Review.

PMID:
24809930
13.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.

Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

14.

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

Jackson RL, Hunt B, MacDonald PA.

BMC Geriatr. 2012 Mar 21;12:11. doi: 10.1186/1471-2318-12-11.

15.

Febuxostat: a new treatment for hyperuricaemia in gout.

Edwards NL.

Rheumatology (Oxford). 2009 May;48 Suppl 2:ii15-ii19. doi: 10.1093/rheumatology/kep088. Review.

16.

Progress in the pharmacotherapy of gout.

Sundy JS.

Curr Opin Rheumatol. 2010 Mar;22(2):188-93. doi: 10.1097/BOR.0b013e3283369014. Review.

PMID:
20110792
17.

Febuxostat for treating chronic gout.

Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008653. doi: 10.1002/14651858.CD008653.pub2. Review.

18.

[New therapeutic options for gout].

Richette P, Ottaviani S, Bardin T.

Presse Med. 2011 Sep;40(9 Pt 1):844-9. doi: 10.1016/j.lpm.2011.02.043. Epub 2011 Jun 17. Review. French.

PMID:
21684104
19.

Safety of urate-lowering therapies: managing the risks to gain the benefits.

Keenan RT.

Rheum Dis Clin North Am. 2012 Nov;38(4):663-80. doi: 10.1016/j.rdc.2012.08.008. Epub 2012 Sep 7. Review.

PMID:
23137576
20.

Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.

Becker MA, MacDonald PA, Hunt B, Gunawardhana L.

Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1011-7. doi: 10.1080/15257770.2011.603715.

PMID:
22132950
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk